MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Decreases Stock Position in Pfizer Inc. $PFE

Key Points

• MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH decreased its stake in Pfizer Inc. by 21.6% during the 2nd quarter, selling 448,907 shares and holding a total of 1,624,887 shares valued at approximately $39.37 million.
• Several analysts have adjusted their price targets for Pfizer, with Bank of America raising it to $28.00 and Morgan Stanley increasing it to $33.00, while Berenberg Bank lowered their target to $25.00.
• Pfizer reported $14.65 billion in quarterly revenue, exceeding estimates, and set its FY 2025 EPS guidance at 2.900-3.100.

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lowered its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 21.6% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,624,887 shares of the biopharmaceutical company's stock after selling 448,907 shares during the quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH's holdings in Pfizer were worth $39,387,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of PFE. Brighton Jones LLC lifted its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after purchasing an additional 618,117 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock worth $498,000 after purchasing an additional 2,087 shares in the last quarter. Vident Advisory LLC purchased a new stake in Pfizer in the 4th quarter worth $248,000. Heck Capital Advisors LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $49,000. Finally, Park Square Financial Group LLC purchased a new stake in shares of Pfizer during the 4th quarter valued at about $128,000. Hedge funds and other institutional investors own 68.36% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Berenberg Bank reduced their price objective on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. Morgan Stanley increased their price objective on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen raised shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday, September 20th. Finally, Citigroup increased their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two investment analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Pfizer currently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Price Performance

Shares of PFE stock opened at $24.07 on Thursday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The company has a market capitalization of $136.82 billion, a P/E ratio of 12.80, a P/E/G ratio of 0.85 and a beta of 0.55. The company's 50-day simple moving average is $24.59 and its two-hundred day simple moving average is $24.18. Pfizer Inc. has a one year low of $20.92 and a one year high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. The firm had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The company's quarterly revenue was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.